Avinger (Avinger) Debt-to-Revenue : 2.25 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Avinger Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Avinger's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.91 Mil. Avinger's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.84 Mil. Avinger's annualized Revenue for the quarter that ended in Mar. 2024 was $7.44 Mil. Avinger's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 2.25.

Avinger Debt-to-Revenue Historical Data

The historical data trend for Avinger's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avinger Debt-to-Revenue Chart

Avinger Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

1.51

1.95

1.53

1.98

2.01

Avinger Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															2.20	2.07	2.09	2.02	2.25

Competitive Comparison of Avinger's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Avinger's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avinger's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avinger's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Avinger's Debt-to-Revenue falls into.

Avinger Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Avinger's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(15.395	+	0)	/	7.652
	=	2.01

Avinger's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(15.907	+	0.835)	/	7.436
	=	2.25

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Avinger Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avinger's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Avinger (Avinger) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avinger Inc (NAS:AVGR) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Chesapeake Drive, Redwood City, CA, USA, 94063

Website

https://avinger.com

Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.

Executives

Crg Partners Iii (cayman) Unlev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Nabeel Paul Subainati	officer: Vice President, Finance	400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
James Cullen	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Mark Weinswig	officer: Chief Financial Officer	EMCORE CORP, 10420 RESEARCH ROAD, SE, ALBUQUERQUE NM 87123
Himanshu Patel	officer: Chief Technology Officer	C/O AVINGER, INC., 400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Jeffrey M Soinski	director, officer: President and CEO	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Tamara Elias	director	400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Simpson John B Ph D Md	director, 10 percent owner	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Matthew Ferguson	officer: CBO, CFO & Treasurer	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
John D. Simpson	officer: Sr. VP, Sales & Marketing	C/O AVINGER, INC., 400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063